newsfilter
← Latest News
GlobeNewswire·

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ESP-2001 Has the